25 April 2024

New modalities: Innovations in peptides as biotherapeutics

Organised by:

SCI’s Fine Chemicals Group

SCI, London, UK

Register Now

Prices start from £75.00

Early bird offer ends 14 March 2024

Synopsis

Peptides as a drug modality offer several advantages over both traditional small molecules and biologics including improved tissue penetration, simpler more modular design characteristics, accessing previously intractable targets and reduced immunogenic risks. The advancement of peptides as therapeutics has been aided by the development of peptide drug conjugates, and this event brings together world class and cutting edge scientists in the fields of peptide and peptide macrocyclic drug and drug conjugate research. The event will give insights into the challenges posed and also the potential for these drugs to make a real world impact, and to interact with active researchers.


Attendees

This event will be of interest to academic and industrial scientists, interested in learning the latest innovations in the field of peptide and peptide macrocyclic drug and drug conjugate developments.


Programme

Thursday 25 April

10.00
Registration and refreshments
Session 1
10.40
Introduction and welcome
Dr Mark Frigerio, Bicycle Therapeutics
10.45
Combining physicochemical measures with natural intelligence to achieve better efficacy with large molecules
Dr Rob Young, Blue Burgundy Ltd
11.25
Cyclic peptide discovery in a more native context
Dr Louise Walport, The Francis Crick Insititute
12.05
Lunch, exhibition and posters
Session 2
13.20
Bugs, plants and peptides: unleashing the power of chemical ecology for sustainable crop protection
Dr Aurelien Bigot, Syngenta Crop Protection
14.00
Peptide conjugates for oncology focussed on radionucleotides
Dr Gemma Mudd, Bicycle Therapeutics
14.40
Refreshment break, exhibition and posters
Session 3
15.10
Platforms for the intracellular generation and high-throughput screening of cyclic peptide libraries
Professor Ali Tavassoli, Chief Scientific Officer and Co-Founder, Curve Therapeutics
15.50
Design and optimization of highly potent, orally bioavailable, PCSK9 macrocycle inhibitors as LDL-cholesterol lowering therapeutics
Dr Elisabetta Bianchi, IRBM
16.30
Peptides as antibody mimics
Sir Gregory Winter, Medical Research Council (MRC) Laboratory of Molecular Biology
17.10
Networking reception

SCI’s Fine Chemicals Group are committed to promoting diversity and equality in the chemical sciences. We aim to identify high quality speakers for all our conferences with full inclusivity where attendees from all backgrounds are welcome. We are open to offering flexible presentation options. 


Sponsorship and exhibition information

For further information and prices, please email conferences@soci.org.


Call for posters
Opportunities are available for a limited number of posters. Interested applicants should send an abstract of maximum one A4 page or 300 words, indicating title and authors to: conferences@soci.org by Thursday 29 February 2024 with the subject line “New modalities: Innovations in peptides as biotherapeutics – poster submission”. An abstract template can be downloaded here.
Venue and Contact

SCI

14/15 Belgrave Square
London
SW1X 8PS

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Fees
Before early bird - ends 14 March 2024
SCI Member - £75
Non-member - £130
SCI Student member - £40

After early bird
SCI Member - £125
Non-member - £180
SCI Student member - £70

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations


Booking Process/Deadlines

Booking terms and conditions


CPD Info

SCI Members attending this meeting are able to claim CPD points.

Accredited cpd Centre - The CPD Standards Office - CPD Provider 41057 - www.cpdstandards.com


Exhibitors

Sponsors

Organising committee
Beatriz Dominguez, SCI / Johnson Matthey
Mark Frigerio, SCI / Bicycle Therapeutics
Helen Horsley, SC I /UCB
Kenneth Ling, SCI / Syngenta
Sarah Major, SCI / Dark Blue Therapeutics